How Enteric Coating Works on Aspirin
Enteric coatings dissolve in the intestine's alkaline environment (pH above 5-6) but resist the stomach's acidic conditions (pH 1-3). This delays aspirin's release until it reaches the small intestine, minimizing direct contact with the stomach lining.[1]
Reduction in Stomach Irritation and Ulcers
Plain aspirin directly irritates gastric mucosa by inhibiting prostaglandins that protect the stomach lining, leading to erosion, bleeding, or ulcers. Enteric-coated versions cut this risk by 50-75% in studies, as the coating prevents topical damage during the 30-60 minutes aspirin spends in the stomach.[2][3]
Evidence from Clinical Studies
A meta-analysis of over 3,000 patients showed enteric-coated aspirin caused fewer gastric erosions (odds ratio 0.38) compared to uncoated forms, especially at daily doses above 1g. Long-term users, like those on cardiovascular therapy, report less dyspepsia and GI bleeding.[4]
Does It Fully Eliminate Risks?
No—systemic effects from absorbed aspirin can still suppress stomach-protecting prostaglandins, raising ulcer risk in high-risk groups (e.g., elderly, NSAID users). Combining with PPIs or misoprostol offers better protection than coating alone.[5]
Comparison to Uncoated Aspirin
| Aspect | Uncoated Aspirin | Enteric-Coated Aspirin |
|--------|------------------|------------------------|
| Onset Time | Faster (15-30 min) | Slower (30-60 min) |
| GI Tolerability | Higher ulceration risk | 2-3x lower incidence |
| Absorption | Immediate | Equivalent bioavailability long-term |
| Cost | Cheaper | 20-50% more expensive |
Coating trades slight delay for safety without losing efficacy.[6]
Who Benefits Most?
Ideal for chronic low-dose users (81mg daily for heart protection) or those with prior GI issues. Not needed for occasional headache relief.[1]
Sources
[1]: FDA Aspirin Labeling Guidelines
[2]: Lancet Study on NSAID Gastropathy
[3]: Gastroenterology Review
[4]: Aliment Pharmacol Ther Meta-Analysis
[5]: American College of Cardiology Guidelines
[6]: DrugPatentWatch Aspirin Formulations